A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
Phase of Trial: Phase II
Latest Information Update: 13 May 2019
Price : $35 *
At a glance
- Drugs VX 150 (Primary)
- Indications Pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 18 Dec 2018 Primary endpoint has been met. (Change from baseline in the weekly average of daily pain intensity on the 11 point numeric rating scale (NRS), as reported in the daily diary), according to a Vertex Pharmaceuticals media release.
- 18 Dec 2018 Results presented in a Vertex Pharmaceuticals media release.
- 07 Dec 2018 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History